CN1615134A - 含有缬沙坦和nep抑制剂的药物组合物 - Google Patents

含有缬沙坦和nep抑制剂的药物组合物 Download PDF

Info

Publication number
CN1615134A
CN1615134A CNA038022680A CN03802268A CN1615134A CN 1615134 A CN1615134 A CN 1615134A CN A038022680 A CNA038022680 A CN A038022680A CN 03802268 A CN03802268 A CN 03802268A CN 1615134 A CN1615134 A CN 1615134A
Authority
CN
China
Prior art keywords
carboxy
propionyl
amino
acid
methionine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038022680A
Other languages
English (en)
Chinese (zh)
Inventor
R·L·韦布
G·M·克桑德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23373410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1615134(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1615134A publication Critical patent/CN1615134A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA038022680A 2002-01-17 2003-01-16 含有缬沙坦和nep抑制剂的药物组合物 Pending CN1615134A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34966002P 2002-01-17 2002-01-17
US60/349,660 2002-01-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201110029600.7A Division CN102091330B (zh) 2002-01-17 2003-01-16 含有缬沙坦和nep抑制剂的药物组合物

Publications (1)

Publication Number Publication Date
CN1615134A true CN1615134A (zh) 2005-05-11

Family

ID=23373410

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201110029600.7A Expired - Lifetime CN102091330B (zh) 2002-01-17 2003-01-16 含有缬沙坦和nep抑制剂的药物组合物
CNA038022680A Pending CN1615134A (zh) 2002-01-17 2003-01-16 含有缬沙坦和nep抑制剂的药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201110029600.7A Expired - Lifetime CN102091330B (zh) 2002-01-17 2003-01-16 含有缬沙坦和nep抑制剂的药物组合物

Country Status (29)

Country Link
EP (1) EP1467728B1 (enExample)
JP (2) JP4820056B2 (enExample)
KR (2) KR100984939B1 (enExample)
CN (2) CN102091330B (enExample)
AT (1) ATE370732T1 (enExample)
AU (1) AU2003206738C1 (enExample)
BE (1) BE2016C025I2 (enExample)
BR (2) BRPI0306907B8 (enExample)
CA (1) CA2472399C (enExample)
CO (1) CO5600999A2 (enExample)
CY (2) CY1106959T1 (enExample)
DE (1) DE60315795T2 (enExample)
DK (1) DK1467728T3 (enExample)
EC (1) ECSP045190A (enExample)
ES (1) ES2290429T3 (enExample)
FR (1) FR16C0019I2 (enExample)
HU (1) HUS1600024I1 (enExample)
IL (2) IL162661A0 (enExample)
LU (1) LU93074I2 (enExample)
MX (1) MXPA04006917A (enExample)
NL (1) NL300811I2 (enExample)
NO (2) NO333191B1 (enExample)
NZ (1) NZ533968A (enExample)
PL (1) PL212318B1 (enExample)
PT (1) PT1467728E (enExample)
RU (1) RU2334513C3 (enExample)
SI (1) SI1467728T1 (enExample)
WO (1) WO2003059345A1 (enExample)
ZA (1) ZA200405117B (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702119A (zh) * 2005-11-09 2012-10-03 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
CN103251587A (zh) * 2007-11-06 2013-08-21 诺瓦提斯公司 基于血管紧张素受体拮抗剂/阻断剂(arb)和中性内肽酶(nep)抑制剂的超结构的双重作用的药物组合物
WO2014198195A1 (zh) * 2013-06-13 2014-12-18 上海翰森生物医药科技有限公司 联芳基取代的4-氨基丁酸衍生物及其制备方法和用途
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
WO2016029828A1 (zh) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
WO2016086798A1 (zh) * 2014-12-03 2016-06-09 上海翰森生物医药科技有限公司 Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
CN105693543A (zh) * 2014-12-15 2016-06-22 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN106138069A (zh) * 2015-04-21 2016-11-23 刘春丽 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
WO2017020841A1 (zh) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
WO2019170136A1 (zh) 2018-03-09 2019-09-12 武汉朗来科技发展有限公司 药物制剂及其应用
US11096928B2 (en) 2016-10-08 2021-08-24 Wuhan Ll Science And Technology Development Co., Ltd. Pharmaceutical composition

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776095A1 (en) * 2004-06-23 2007-04-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists
AU2005318365B2 (en) * 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
WO2007106708A2 (en) * 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
CZ300801B6 (cs) * 2006-06-07 2009-08-12 Helvetia Pharma A.S. Kompozice s valsartanem v pevných lékových formách
BRPI0806700A8 (pt) 2007-01-12 2019-01-22 Novartis Ag processo
GB0708507D0 (en) 2007-05-02 2007-06-13 Queen Mary & Westfield College Substituted phosphonates and their use
CN101774941A (zh) * 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
AU2011295170B2 (en) 2010-08-23 2014-12-18 Novartis Ag Process for the preparation of intermediates for the manufacture of NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
ES2879550T3 (es) 2012-08-24 2021-11-22 Novartis Ag Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
KR20150119107A (ko) 2013-02-14 2015-10-23 노파르티스 아게 개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체
EP2956464B1 (en) 2013-02-14 2018-03-28 Novartis AG Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
JP2016530282A (ja) 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
HUE047186T2 (hu) 2013-08-26 2020-04-28 Novartis Ag Új alkalmazás
WO2016037098A1 (en) * 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
WO2016074651A1 (en) 2014-11-14 2016-05-19 Zentiva, K.S. A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
AU2015319831B2 (en) * 2014-12-08 2019-02-14 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
EP3302460A1 (en) 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
EP3355880A1 (en) 2015-08-28 2018-08-08 Novartis AG New use
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
EP3386945A1 (en) 2015-12-11 2018-10-17 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
CA3010778C (en) 2016-02-03 2024-02-27 Novartis Ag Galenic formulations of organic compounds
HK1256865A1 (zh) 2016-02-03 2019-10-04 Novartis Ag 有机化合物的盖伦制剂
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
EA202090398A1 (ru) 2017-07-28 2020-05-15 Синтон Б.В. Фармацевтическая композиция, включающая сакубитрил и валсартан
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2021158084A1 (ko) * 2020-02-07 2021-08-12 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210101164A (ko) 2020-02-07 2021-08-18 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20200020746A (ko) 2020-02-07 2020-02-26 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
CN120390636A (zh) 2022-12-20 2025-07-29 斯法姆公司 包含钠-葡萄糖协同转运蛋白2抑制剂和血管紧张素ⅱ受体阻滞剂的口服药物制剂
KR20240099023A (ko) 2022-12-20 2024-06-28 주식회사 티에치팜 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 심혈관 질환 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0498361A3 (en) * 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CA2168066A1 (en) * 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
EP1267855A2 (en) * 2000-04-03 2003-01-02 Bristol-Myers Squibb Company Vasopeptidase inhibitors to treat isolated systolic hypertension
KR100659644B1 (ko) * 2000-06-22 2006-12-21 노파르티스 아게 고형 발사르탄 약제학적 조성물
AU8967201A (en) * 2000-07-19 2002-01-30 Novartis Ag Valsartan salts
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098689B (zh) * 2005-11-09 2013-02-13 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
CN102702119A (zh) * 2005-11-09 2012-10-03 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
CN102702119B (zh) * 2005-11-09 2016-01-20 诺华股份有限公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
TWI484982B (zh) * 2007-11-06 2015-05-21 Novartis Ag 固體口服劑型及相關方法、組合物及用途
CN103251587A (zh) * 2007-11-06 2013-08-21 诺瓦提斯公司 基于血管紧张素受体拮抗剂/阻断剂(arb)和中性内肽酶(nep)抑制剂的超结构的双重作用的药物组合物
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
WO2014198195A1 (zh) * 2013-06-13 2014-12-18 上海翰森生物医药科技有限公司 联芳基取代的4-氨基丁酸衍生物及其制备方法和用途
CN104230865A (zh) * 2013-06-13 2014-12-24 上海翰森生物医药科技有限公司 联芳基取代的4-氨基丁酸衍生物及其制备方法和用途
CN105143183B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
WO2016029828A1 (zh) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
WO2016086798A1 (zh) * 2014-12-03 2016-06-09 上海翰森生物医药科技有限公司 Nep抑制剂结晶型游离酸、钙盐多晶型及其制备方法和应用
CN105693543A (zh) * 2014-12-15 2016-06-22 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
CN106138069A (zh) * 2015-04-21 2016-11-23 刘春丽 作为治疗来自非角化复层上皮组织的不适的局部药剂的1-二仲丁基膦酰基戊烷
WO2017020841A1 (zh) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
US11096928B2 (en) 2016-10-08 2021-08-24 Wuhan Ll Science And Technology Development Co., Ltd. Pharmaceutical composition
WO2019170136A1 (zh) 2018-03-09 2019-09-12 武汉朗来科技发展有限公司 药物制剂及其应用
US11337972B2 (en) 2018-03-09 2022-05-24 Wuhan Ll Science And Technology Development Co., Ltd. Pharmaceutical preparation and use thereof

Also Published As

Publication number Publication date
WO2003059345A1 (en) 2003-07-24
DE60315795T2 (de) 2008-06-05
PT1467728E (pt) 2007-11-14
CA2472399C (en) 2012-02-21
DE60315795D1 (de) 2007-10-04
NL300811I2 (enExample) 2016-07-27
BR122018015003B8 (pt) 2021-07-27
NO2016009I2 (no) 2016-05-18
IL162661A (en) 2010-11-30
ECSP045190A (es) 2004-08-27
ZA200405117B (en) 2005-08-31
CO5600999A2 (es) 2006-01-31
PL369773A1 (en) 2005-05-02
BR0306907A (pt) 2004-12-21
HUS1600024I1 (hu) 2016-06-28
CY2016013I1 (el) 2016-10-05
MXPA04006917A (es) 2004-12-06
FR16C0019I2 (fr) 2017-12-08
IL162661A0 (en) 2005-11-20
AU2003206738C1 (en) 2020-01-30
JP2011207898A (ja) 2011-10-20
RU2334513C2 (ru) 2008-09-27
KR100984939B1 (ko) 2010-10-01
ATE370732T1 (de) 2007-09-15
BE2016C025I2 (enExample) 2022-05-17
EP1467728B1 (en) 2007-08-22
FR16C0019I1 (enExample) 2016-06-24
KR20040078127A (ko) 2004-09-08
JP2005514441A (ja) 2005-05-19
CY2016013I2 (el) 2016-10-05
NZ533968A (en) 2006-10-27
LU93074I2 (fr) 2016-07-18
AU2003206738A1 (en) 2003-07-30
PL212318B1 (pl) 2012-09-28
RU2004125178A (ru) 2005-06-10
RU2334513C3 (ru) 2017-10-24
ES2290429T3 (es) 2008-02-16
EP1467728A1 (en) 2004-10-20
DK1467728T3 (da) 2007-12-27
BRPI0306907B1 (pt) 2018-10-30
BRPI0306907B8 (pt) 2021-05-25
JP4820056B2 (ja) 2011-11-24
CY1106959T1 (el) 2012-01-25
CN102091330B (zh) 2015-04-08
CN102091330A (zh) 2011-06-15
NO333191B1 (no) 2013-03-25
NO2016009I1 (no) 2016-05-18
CA2472399A1 (en) 2003-07-24
KR20100057704A (ko) 2010-05-31
NO20043380L (no) 2004-10-07
SI1467728T1 (sl) 2008-02-29
AU2003206738B2 (en) 2006-12-21
BR122018015003B1 (pt) 2018-11-21
KR100984939B9 (ko) 2024-07-17

Similar Documents

Publication Publication Date Title
CN1615134A (zh) 含有缬沙坦和nep抑制剂的药物组合物
US8796331B2 (en) Methods of treatment and pharmaceutical composition
AU2006212772B2 (en) Combination of organic compounds
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
WO2007045663A2 (en) Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
JP2021522247A (ja) 肝疾患における好中球エラスターゼ阻害薬の使用
US20080261958A1 (en) Combination of Organic Compounds
CN101151027A (zh) 有机化合物的组合
AU2006202999A1 (en) Pharmaceutical compositions comprising valsartan and NEP inhibitors
MX2007009663A (en) Combination of organic compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050511